Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
Aadi, accident, aforementioned, aggressive, Amsterdam, anesthesiology, Annex, Aranda, archived, Array, atrial, authorised, authoritative, backbone, BBB, BCR, beigene, Bioscience, blockade, boundary, brain, Bristol, Britain, Brukinsa, Bruton, calcium, Calquence, cardiovascular, Carter, Caryn, cautionary, Celegene, cerebrospinal, CHMP, clinician, clock, closure, CNS, Commissioner, constitutionality, contemplate, covalent, crossing, crystallized, CTA, database, delegated, Delta, derecognized, dialogue, discriminatory, dismissed, Donetsk, downstream, downturn, draft, EC, EGFR, embedded, England, evobrutinib, evolution, expiry, extracellular, FD, fenebrutinib, FeRx, fibrillation, float, forensic, GB, Great, harbor, Helsinki, hematologic, hematological, hematopoietic, ibrutinib, ID, image, Imbruvica, instructed, intracellular, invasion, laid, Laura, leave, left, Luhansk, Lycera, lymphoma, MAA, malignant, malware, Medimmune, mercaptopurine, methotrexate, MHRA, military, Milligan, modest, modestly, multidisciplinary, multifaceted, necessitate, neurological, neurotoxicity, nurse, obfuscate, Ono, opposed, orelabrutinib, ORR, paragraph, Parliament, partnership, PCNSL, PCSNL, Peterson, pharmacovigilance, pirtobrutinib, plc, polychemotherapy, principle, proactive, proportionality, radiographic, radiotherapy, ransomware, rapporteur, rash, reconsider, recurrent, reevaluation, reframing, relizabrutinib, relocation, remibrutinib, Richard, rilzabrutinib, RMP, Russian, safest, Sandra, Scotland, Secretary, slowdown, somwhat, spiked, streamline, suboptimal, summer, Syndax, tailored, TCA, TEC, textual, thought, titrate, tolebrutinib, transcription, transposed, Ukraine, unemployment, unintended, unlimited, unnecessary, vacated, vaccine, variant, variation, Velexbru, verity, vitreoretinal, voluntarily, watched, wholesale, worker, Wyeth
Removed:
AA, Aberrant, Acceleron, adherence, adhesion, airflow, airway, allergic, allocating, AMT, antagonist, asthma, atopic, benralizumab, breast, bronchial, card, characterization, checkpoint, chemotherapy, Chiesi, Cinqair, cold, combine, comment, comparator, confirming, constriction, correlated, coughing, CRS, cytokine, cytotoxic, discontinued, disorder, dupilumab, Dupixent, electrocardiographic, eliminating, emerged, eosinophilic, esophageal, evasion, exam, exclusionary, expiratory, explore, Farmaceutici, Fasenra, fevipiprant, field, forfeiture, gastric, gather, Genentech, GlaxoSmithKline, Head, helper, holding, hyperactivity, ICS, Idorsia, immunologically, inappropriate, infiltration, influx, inseverable, integrin, intermittent, intrahepatic, IRS, Japanese, Judge, justified, Ki, LABA, Lake, liaison, lipid, liver, LP, lt, Luisa, mediating, medium, mepolizumab, microenvironment, montelukast, morning, nanomolar, nasal, Nucala, omalizumab, online, pancreatic, peak, PEF, pertaining, Pharma, phenotype, prescribe, presence, prominent, proportion, prostaglandin, prostate, Pulmagen, QS, qualifying, recapture, recruited, Regeneron, removed, repealed, repealing, replaced, rescue, residence, reslizumab, reversibly, revolutionized, rulemaking, Sanofi, shared, sputum, standardized, steroid, suggest, Suite, suppressive, suppressor, surgery, swelling, TEAE, Teijin, Teva, tezepelumab, thousand, TME, topical, toxicology, traceability, tumor, uncontrolled, urticaria, violating, visit, wheezing, white, Xolair
Filing tables
Filing exhibits
Related press release
Associated GOSS transcripts
GOSS similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-229586) pertaining to the Gossamer Bio, Inc. 2017 Equity Incentive Plan, Gossamer Bio, Inc. 2019 Incentive Award Plan, and Gossamer Bio, Inc. 2019 Employee Stock Purchase Plan of our report dated March 3, 2022, with respect to the consolidated financial statements of Gossamer Bio, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2021.
/s/ Ernst & Young LLP
San Diego, California
March 3, 2022